272 related articles for article (PubMed ID: 15632250)
1. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
2. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
[TBL] [Abstract][Full Text] [Related]
5. Bexarotene: a clinical review.
Farol LT; Hymes KB
Expert Rev Anticancer Ther; 2004 Apr; 4(2):180-8. PubMed ID: 15056048
[TBL] [Abstract][Full Text] [Related]
6. Nonclassical retinoids and lung carcinogenesis.
Dragnev KH; Petty WJ; Ma Y; Rigas JR; Dmitrovsky E
Clin Lung Cancer; 2005 Jan; 6(4):237-44. PubMed ID: 15694016
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.
Govindan R; Crowley J; Schwartzberg L; Kennedy P; Williams C; Ekstrand B; Sandler A; Jaunakais D; Bolejack V; Ghalie R
J Clin Oncol; 2006 Oct; 24(30):4848-54. PubMed ID: 17050870
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
9. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW
Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650
[TBL] [Abstract][Full Text] [Related]
10. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
Dragnev KH; Petty WJ; Shah SJ; Lewis LD; Black CC; Memoli V; Nugent WC; Hermann T; Negro-Vilar A; Rigas JR; Dmitrovsky E
Clin Cancer Res; 2007 Mar; 13(6):1794-800. PubMed ID: 17363535
[TBL] [Abstract][Full Text] [Related]
11. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Wakelee HA; Takimoto CH; Lopez-Anaya A; Chu Q; Middleton G; Dunlop D; Ramlau R; Leighl N; Rowinsky EK; Hao D; Zatloukal P; Jacobs CD; Rodon J
Cancer Chemother Pharmacol; 2012 Feb; 69(2):563-71. PubMed ID: 22057855
[TBL] [Abstract][Full Text] [Related]
12. Bexarotene ligand pharmaceuticals.
Hurst RE
Curr Opin Investig Drugs; 2000 Dec; 1(4):514-23. PubMed ID: 11249708
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials.
Tyagi P
Clin Lung Cancer; 2005 Jul; 7(1):17-9. PubMed ID: 16098239
[No Abstract] [Full Text] [Related]
14. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
[TBL] [Abstract][Full Text] [Related]
15. New agents in advanced non-small-cell lung cancer treatment.
Ricciardi S; de Marinis F
Oncology; 2009; 77 Suppl 1():103-12. PubMed ID: 20130438
[TBL] [Abstract][Full Text] [Related]
16. Bexarotene and erlotinib for aerodigestive tract cancer.
Dragnev KH; Petty WJ; Shah S; Biddle A; Desai NB; Memoli V; Rigas JR; Dmitrovsky E
J Clin Oncol; 2005 Dec; 23(34):8757-64. PubMed ID: 16314636
[TBL] [Abstract][Full Text] [Related]
17. Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer.
Luo W; Schork NJ; Marschke KB; Ng SC; Hermann TW; Zhang J; Sanders JM; Tooker P; Malo N; Zapala MA; Dziewanowska ZE; Negro-Vilar A; Meglasson MD
Anticancer Res; 2011 Jun; 31(6):2303-11. PubMed ID: 21737656
[TBL] [Abstract][Full Text] [Related]
18. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
Yen WC; Lamph WW
Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282
[TBL] [Abstract][Full Text] [Related]
19. Prevention of lung cancer progression by bexarotene in mouse models.
Wang Y; Zhang Z; Yao R; Jia D; Wang D; Lubet RA; You M
Oncogene; 2006 Mar; 25(9):1320-9. PubMed ID: 16247446
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.
Yen WC; Prudente RY; Lamph WW
Breast Cancer Res Treat; 2004 Nov; 88(2):141-8. PubMed ID: 15564797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
